HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
N(4)- benzoyl- 2',3'- dideoxy- 2',3'- didehydrocytidine
structure given in first source
Also Known As:
Bz-DDCN
Networked:
1
relevant articles (
0
outcomes,
0
trials/studies)
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Pyrimidines: 510
Pyrimidine Nucleosides: 50
Cytidine: 535
Deoxycytidine: 307
Zalcitabine: 278
N(4)-benzoyl-2',3'-dideoxy-2',3'-didehydrocytidine: 1
Nucleic Acids, Nucleotides, and Nucleosides: 1
Nucleosides: 6847
Pyrimidine Nucleosides: 50
Cytidine: 535
Deoxycytidine: 307
Zalcitabine: 278
N(4)-benzoyl-2',3'-dideoxy-2',3'-didehydrocytidine: 1
Deoxyribonucleosides: 34
Deoxycytidine: 307
Zalcitabine: 278
N(4)-benzoyl-2',3'-dideoxy-2',3'-didehydrocytidine: 1
Dideoxynucleosides: 27
Zalcitabine: 278
N(4)-benzoyl-2',3'-dideoxy-2',3'-didehydrocytidine: 1
Related Diseases
1.
Acquired Immunodeficiency Syndrome (AIDS)
09/01/1989 - "
N4-Benzoyl-2',3'-dideoxy-2',3'-didehydrocytidine (Bz-DDCN) was synthesized as a novel prodrug of 2',3'-dideoxy-2',3'-didehydrocytidine (DDCN), which is a reverse transcriptase inhibitor and is considered to be a potential anti-acquired immunodeficiency syndrome agent.
"
Related Drugs and Biologics
1.
Reverse Transcriptase Inhibitors
2.
Prodrugs